CelSci
Open
$3.12
Prev. Close
$3.12
High
$3.15
Low
$3.12
Market Snapshot
$24.47M
-1.0
-14.36
44
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
emptyResult
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Recently from Cashu
CelSci Stock Highlights Nucleus Security's Leadership in Continuous Vulnerability Management Standards
Nucleus Security Sets Industry Standards in Vulnerability Management Nucleus Security positions itself as a frontrunner in the cybersecurity domain, particularly in Continuous Vulnerability Management…
CelSci's Nucleus Security Named Leader in Continuous Vulnerability Management by GigaOm Radar 2025
Nucleus Security Recognized as Leader in Continuous Vulnerability Management Nucleus Security, a prominent player in unified vulnerability and exposure management, solidifies its position in the cyber…
Nucleus Security Achieves Leadership in Continuous Vulnerability Management Solutions
Nucleus Security Solidifies Leadership in Continuous Vulnerability Management Nucleus Security reaffirms its position as a trailblazer in the field of Continuous Vulnerability Management (CVM) with it…
CelSci Enhances Patient Engagement in Immunotherapy Trials for Improved Cancer Treatment Outcomes
CelSci's Advancements in Immunotherapy and Patient Engagement CelSci Corporation, a biotechnology company specializing in immunotherapy for cancer treatment, advances its mission by enhancing patient…